Efgartigimod for treating antibody-positive generalised myasthenia gravis

Notice of Appeal

Efgartigimod for treating generalised myasthenia gravis [ID4003]

NICE has received 2 appeals, that fall within one or more of the two strictly limited grounds for appeal, against the Final Draft Guidance on the above technology from the following organisations:

• Argenx UK Limited 
• Myaware UK

The appeal panel will convene on Tuesday 6 May at 10:00am via Zoom to hear oral representations from the appellants.

Members of the public, including consultees and commentators for this appraisal, and the press, may request to attend the hearing.

Where possible, requests to attend should be made using the registration link that will be available on our website from Thursday 20 February 2025. The registration period for this appeal will end at 4:00pm on Tuesday 29 April 2025.

Further details relating to public attendance at this appeal are available on the same webpage as above.